Kestrel Therapeutics secured FDA IND clearance for KST‑6051, an oral pan‑KRAS inhibitor targeting KRAS‑driven cancers, and plans a first‑in‑human phase I FALCON study by the end of the first quarter. The IND clearance positions Kestrel among a growing group pursuing direct KRAS targeting beyond the common G12C subtype. KST‑6051’s oral small‑molecule profile may enable broader dosing strategies and combinability with standard agents. The clearance underscores continued investor and regulatory focus on KRAS as a high‑value oncology target.